Investorideas.com
Search  Follow Investorideas on Twitter  Investorideas is on Facebook  Investorideas is on Google Plus  Investorideas is on Youtube  Investorideas is on Pinterest  Investorideas is on tumblr  Investorideas is on LinkedIn  Investorideas is on Medium  Investorideas RSS 


Investorideas podcasts on iTunes, Google Play Music and iHeart.com


Biopharma Gets Green Light for Hypertension Study

Source: Streetwise Reports

 

September 15, 2017 (Investorideas.com Newswire) Jason McCarthy, an analyst at Maxim Group, discussed this France-based biotech firm's near-term clinical trial and catalysts.


A Sept. 11 research report revealed Quantum Genomics SA's (ALQGC:PA; QNNTF:OTXQX) "Phase 2 study (NEW-HOPE, n=250) of brain aminopeptidase A inhibitor (BAPAI) candidate QGC001 has received regulatory clearance and is on track to initiate in Q4/17," wrote analyst Jason McCarthy with Maxim Group. "BAPAIs are a new class of drug that targets the brain renin-angiotensin-aldosterone system (RAAS)."

Medical data suggest "20–25% of patients have poorly controlled blood pressure and are resistant to multiple drugs currently available; many of these patients have low renin-high vasopressin hypertension (LRHV)," indicated McCarthy.

Quantum's BAPAI, QGC001, might help. "By targeting the brain RAAS versus the periphery, QGC001 can potentially control blood pressure in these patients," the analyst explained, reiterating that "what makes BAPAIs unique is that they act centrally in the brain to regulate blood pressure in hypertensive patients and have no impact on healthy (normotensive) patients."

As for the study design, NEW-HOPE "will enroll 250 hypertensive patients with at least 50% of patients being ethnic minorities (LRHV)," and treat them for eight weeks, explained McCarthy. Further, NEW-HOPE should "complete enrollment in Q4/18 and report data in mid-2019."

Maxim expects catalysts "over the next year as Quantum continues to advance its BAPAI platform in hypertension and heart failure," the analyst wrote.

One catalyst is the heart failure study (QGC101). "The n=75 study is ongoing at 15 centers" and "should be fully enrolled in Q4/17 with data expected in H1/18," noted McCarthy.

A second catalyst is the anticipated initiation of "a combination study in hypertension evaluating a BAPAI plus a diuretic," although the company hasn't yet disclosed a start date, McCarthy said. "QGC001, in combination with currently approved therapies, could provide a more effective and more well-tolerated approach for treating high blood pressure and chronic heart failure."

With respect to BAPAIs' potential, McCarthy suggested, "Novel combination approaches that include BAPAIs could expand the hypertension and heart failure drug markets, in our view. The new European intellectual property covers the combination therapy of QGC001 with multiple medications that are widely prescribed to treat hypertension and heart failure."

Maxim Group has a rating of Buy and a 12-month target price of €12 per share on Quantum Genomics, which is currently trading at about €3.10 per share.

Disclosure:

1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.

2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.

4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.


BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks


More Info:

Investorideas.com Newswire

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.


Questrade Democratic Pricing - 1 cent per share, $4.95 min / $9.95 max



Join Investor Ideas Members to access the Renewable Energy stocks directory, water stocks, biotech stocks, defense stocks directories and the Insiders Corner